Lesson plan
Lorundrostat
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants. In a meta-analysis analysing data from 3 randomized controlled trials over 3 months of clinical use, lorundrostat at 50-100mg/day was found to be effective in lowering blood pressure, with associated issues of mild increase in serum potassium levels and decline in the glomerular filtration rate
Article summary
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants. In a meta-analysis analysing data from 3 randomized controlled trials over 3 months of clinical use, lorundrostat at 50-100mg/day was found to be effective in lowering blood pressure, with associated issues of mild increase in serum potassium levels and decline in the glomerular filtration rate
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.